10-KPeriod: FY2020

THERMO FISHER SCIENTIFIC INC. Annual Report, Year Ended Dec 31, 2020

Filed February 25, 2021For Securities:TMO

Summary

Thermo Fisher Scientific Inc. reported significant revenue growth in 2020, reaching $32.22 billion, an increase of 26% over 2019. This growth was substantially driven by the company's pivotal role in addressing the COVID-19 pandemic, with sales of products related to COVID-19 testing and treatment contributing $6.63 billion. The Life Sciences Solutions segment experienced exceptional growth of 77%, largely fueled by demand for COVID-19 diagnostics and bioproduction services. Despite challenges in certain industrial and academic markets due to the pandemic, overall operating income more than doubled to $7.79 billion, with an improved operating margin of 24.2% compared to 18.0% in the prior year. Financially, Thermo Fisher demonstrated strong operational cash flow of $8.29 billion in 2020. The company maintained a healthy liquidity position with $10.33 billion in cash and cash equivalents as of December 31, 2020, and sufficient borrowing capacity to meet its financial obligations. The company also continued its share repurchase program, authorizing an additional $2.50 billion in late 2020 and repurchasing $1.50 billion early in 2021. The strong performance, driven by both organic growth and strategic acquisitions, positions Thermo Fisher well for continued expansion and innovation in serving the scientific community.

Financial Highlights

56 data points
Beta

Revenue

$32.22B

Net Income

$6.38B

19.8% Net Margin

EPS (Diluted)

$15.96

Total Assets

$69.05B

Cash & Equivalents

$10.34B

Free Cash Flow

$6.82B

Financial Statements
Beta
Revenue$32.22B
R&D Expenses$1.18B
SG&A Expenses$6.93B
Operating Expenses$24.42B
Operating Income$7.79B
Interest Expense$553.00M
Net Income$6.38B
EPS (Basic)$16.09
EPS (Diluted)$15.96
Shares Outstanding (Basic)396.00M
Shares Outstanding (Diluted)399.00M

Key Highlights

  • 1Total revenues grew by 26% to $32.22 billion in 2020, primarily driven by strong demand for COVID-19 related products and services.
  • 2The Life Sciences Solutions segment saw a remarkable 77% revenue increase, largely due to its contribution to COVID-19 testing and bioproduction.
  • 3Operating income surged by 70% to $7.79 billion, with operating margin improving to 24.2% from 18.0% in 2019.
  • 4Cash flow from operations reached $8.29 billion in 2020, reflecting robust operational performance.
  • 5The company ended 2020 with a strong liquidity position, holding $10.33 billion in cash and cash equivalents.
  • 6Significant revenue contribution from COVID-19 testing and treatment products, totaling $6.63 billion in 2020.
  • 7Continued strategic capital allocation through share repurchases, with a new authorization of $2.50 billion in late 2020.

Frequently Asked Questions

COVID-19 was a significant driver of Thermo Fisher's 2020 performance. The company generated $6.63 billion in revenue from products and services directly related to COVID-19 testing, diagnosis, and treatment development. While some industrial and academic markets saw reduced demand due to pandemic-related disruptions, the overall impact was a substantial net positive, particularly boosting the Life Sciences Solutions and Specialty Diagnostics segments.

Thermo Fisher demonstrated strong financial health and liquidity. The company reported $8.29 billion in cash flow from operations for 2020 and ended the year with $10.33 billion in cash and cash equivalents. Management believes its current cash reserves, future operating cash flow, and available credit facilities are sufficient to meet its foreseeable financial needs.

Thermo Fisher actively manages its capital. In addition to investing in organic growth and strategic acquisitions (such as Brammer Bio in 2019), the company is committed to returning capital to shareholders. It had an existing share repurchase authorization and, in late 2020, replaced it with a new authorization for up to $2.50 billion, of which $1.00 billion was available for future repurchases as of the filing date. The company also repurchased $1.50 billion of stock in early 2021.

The primary growth driver across all segments was the demand related to the COVID-19 pandemic. Specifically, the Life Sciences Solutions segment grew by 77% due to COVID-19 testing and bioproduction needs. Specialty Diagnostics saw a 44% increase driven by COVID-19 treatment products and healthcare channel sales. Laboratory Products and Services increased by 16%, supported by pandemic response and existing product/service demand. The Analytical Instruments segment experienced a slight decline of 7% due to reduced demand from industrial and academic customers affected by COVID-19, though it showed signs of recovery in the fourth quarter.